QED Therapeutics clinical trials
A subsidiary of BridgeBio
The registry lists 11 studies whose lead sponsor is QED Therapeutics. 5 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 26, 2026.
Registry sponsor names on this page
- QED Therapeutics, a BridgeBio company8 studies
- QED Therapeutics, Inc.3 studies
Something wrong with this grouping? Tell us on the BridgeBio page.
Studies
Recruiting first, then most recently updated. Showing 11 of 11. All BridgeBio studies →
- Extension Study of Infigratinib in Children With Achondroplasia (ACH)Enrolling by invitationNCT05145010Phase 2
Sponsor listed in the registry: QED Therapeutics, a BridgeBio company
- Open-Label, Long-Term, Extension Study of Infigratinib in Children With HypochondroplasiaEnrolling by invitationNCT07393373Phase 2
Sponsor listed in the registry: QED Therapeutics, a BridgeBio company
- Prospective Clinical Assessment Study in Children With HypochondroplasiaRecruitingNCT06410976
Sponsor listed in the registry: QED Therapeutics, a BridgeBio company
- An Interventional Study of Infigratinib in Children With HypochondroplasiaEnrolling by invitationNCT06873035Phase 2/3
Sponsor listed in the registry: QED Therapeutics, a BridgeBio company
- Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)RecruitingNCT07169279Phase 2
Sponsor listed in the registry: QED Therapeutics, a BridgeBio company
- Prospective Clinical Assessment Study in Children With Achondroplasia (ACH)CompletedNCT04035811
Sponsor listed in the registry: QED Therapeutics, a BridgeBio company
- A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With AchondroplasiaCompletedNCT06164951Phase 3
Sponsor listed in the registry: QED Therapeutics, a BridgeBio company
- Study of Infigratinib in Children With AchondroplasiaCompletedNCT04265651Phase 2
Sponsor listed in the registry: QED Therapeutics, a BridgeBio company
- Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/TranslocationsTerminatedNCT03773302Phase 3
Sponsor listed in the registry: QED Therapeutics, Inc.
- Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic AlterationsTerminatedNCT04197986Phase 3
Sponsor listed in the registry: QED Therapeutics, Inc.
- A Phase II, Single Arm Study of BGJ398 in Patients With Advanced CholangiocarcinomaTerminatedNCT02150967Phase 2
Sponsor listed in the registry: QED Therapeutics, Inc.